Pradžia › Šlapimo pūslės vėžys › Masčusetsas › Boston
Šlapimo pūslės vėžys klinikiniai tyrimai Boston, MA
26 tyrimai dėl Šlapimo pūslės vėžys ieško dalyvių vietose Boston ir aplinkui (apytiksliai 30 mylių spinduliu). Atidarykite tyrimą, kad pamatytumėte, kas gali dalyvauti ir kaip susisiekti su tyrimo komanda.
Oficialus tyrimo tekstas (anglų kalba)
Ieškote dalyvių tyrimui? Pateikite jį šio puslapio viršuje – $99 už 30 dienų →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Renkami dalyviai1 fazė
- Massachusetts General Hospital, Boston
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Renkami dalyviai3 fazė
- Brigham and Women's Hospital, Boston
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Renkami dalyviai2 fazė
- Massachusetts General Hospital Cancer Center, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Renkami dalyviai2 fazė
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Renkami dalyviai1 fazė
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Renkami dalyviai2 fazė
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Patient-Centered Surgical Prehabilitation
Renkami dalyviaiLaukiami sveiki savanoriai
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Renkami dalyviai3 fazė
- Dana Farber Cancer Institute ( Site 0783), Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Renkami dalyviai3 fazė
- Massachusetts General Hospital, Boston
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Renkami dalyviai
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Renkami dalyviai1 fazė
- Dana-Farber Cancer Institute, Boston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Renkami dalyviai2 fazė
- Brigham and Women's Hospital, Boston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Renkami dalyviai2 fazė
- Brigham and Women's Hospital, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Renkami dalyviai1 fazė
- Massachusetts General Hospital, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Renkami dalyviai3 fazė
- Massachusetts General Hospital Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Renkami dalyviai1/2 fazė
- Massachusetts General Hospital Cancer Center, Boston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Renkami dalyviai1/2 fazė
- Brigham and Women's Hospital, Boston
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Renkami dalyviai2/3 fazė
- Local Institution - 0195, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Renkami dalyviai2 fazė
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Renkami dalyviai3 fazė
- Research Site, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Renkami dalyviai1 fazė
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- ir dar 2
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Renkami dalyviaiStebimasis tyrimas
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Renkami dalyviai
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
Renkami dalyviai1/2 fazė
- Dana Farber Cancer Institute, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Renkami dalyviai
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
Renkami dalyviai3 fazė
- Brigham and Women's Hospital, Boston
Šlapimo pūslės vėžys tyrimai kituose miestuose
- New York City, NY35 tyrimai
- Nashville, TN31 tyrimas
- Houston, TX31 tyrimas
- Dallas, TX27 tyrimai
- Washington, DC26 tyrimai
- Los Angeles, CA24 tyrimai
- Baltimore, MD24 tyrimai
- St. Louis, MO22 tyrimai
- Philadelphia, PA21 tyrimas
- Seattle, WA21 tyrimas
- Edison, NJ21 tyrimas
- Chicago, IL21 tyrimas
Kiti tyrimai Boston
- Krūties vėžys111 tyrimai
- Nedidelinių ląstelių plaučių vėžys90 tyrimai
- Vėžys (visų tipų)86 tyrimai
- Storosios ir tiesiosios žarnos vėžys63 tyrimai
- Metastatinis vėžys63 tyrimai
- Plaučių vėžys62 tyrimai
- Kiaušidžių vėžys61 tyrimas
- Prostatos vėžys59 tyrimai
- Depresija52 tyrimai
- Endometrio vėžys50 tyrimai
- Širdies nepakankamumas44 tyrimai
- Ūmi mieloidinė leukemija44 tyrimai
Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.